PCM
PCRX icon

Palisade Capital Management’s Pacira BioSciences PCRX Stock Holding History

Palisade Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,500
Closed -$219K – 575
2016
Q2 		$219K Buy
6,500
+2,250
+53% +$111K 0.01% 514
2016
Q1 		$225K Buy
4,250
+1,250
+42% +$73.1K 0.01% 515
2015
Q4 		$230K Sell
3,000
-4,500
-60% -$255K 0.01% 511
2015
Q3 		$308K Buy
7,500
+2,000
+36% +$123K 0.01% 492
2015
Q2 		$389K Buy
5,500
+1,250
+29% +$98.4K 0.01% 485
2015
Q1 		$378K Buy
+4,250
New +$431K 0.01% 468

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return